Prevent RFEs on I-693: Menactra vs Menveo Vaccine Rules
Both Menactra and Menveo are quadrivalent conjugate vaccines that protect against meningococcal serogroups A, C, W, and Y. The main practical difference is age: Menveo can be given starting at 2 months, while Menactra’s approval begins at 9 months, and CDC generally has no brand preference once a patient is old enough for either. For a Form I-693 immigration medical exam, the vaccine choice usually comes down to age eligibility, available documentation, and what your civil surgeon has on hand.
TL;DR:
- Menveo is the only option for infants starting at 2 months, while Menactra is approved only from 9 months onwards.
- Both vaccines cover serogroups A, C, W, and Y, but neither protects against serogroup B.
- For ages 9 months to 55 years, CDC considers Menactra and Menveo interchangeable, but only Menveo is licensed under 9 months.
- Reconstitution steps differ, with Menveo (two-vial) requiring mixing and Menactra being a single vial, affecting clinic workflow.
- Vaccine protection wanes over time, necessitating a booster at age 16, with no significant difference between the brands’ durability.
Table of Contents
- What MenACWY vaccines cover and how they fit into U.S. schedules
- How age approvals and dosing schedules actually differ
- What the safety data show about reactions and rare events
- When brands are interchangeable and when they are not
- Dosing schedules and administration by age group
- What this means for your Form I-693 civil surgeon exam
- Getting ready for your appointment
- The bottom line on choosing between these vaccines
- Does insurance cover the cost of either vaccine
- Can these vaccines be given alongside other shots
- How long does protection last with each vaccine
- Clinic perspective: what we see with vaccination records
- Schedule your exam and vaccination review
- Sources
- FAQ
What MenACWY vaccines cover and how they fit into U.S. schedules
MenACWY vaccines target four of the six known disease-causing serogroups of Neisseria meningitidis, a bacterium that can cause meningitis and bloodstream infections. Menactra and Menveo both belong to this category, and neither one covers serogroup B, which requires a separate vaccine (MenB) with its own schedule and brand options.
The distinction matters because people sometimes assume “meningococcal vaccine” means one shot covers everything. It does not. A patient who received only MenACWY as a teenager is not protected against serogroup B disease, and a civil surgeon reviewing immigration records needs to know which serogroups a given vaccine addressed before checking a box on Form I-693.
MenACWY vaccines are used in three main contexts in the United States:
- Routine adolescent immunization, with a first dose at 11 or 12 years and a booster around age 16.
- High-risk groups, including people with certain immune conditions, microbiologists who handle the bacteria, and military recruits.
- Outbreak response and travel, particularly for people heading to regions with higher meningococcal circulation, such as parts of sub-Saharan Africa.
Menactra and Menveo are the two MenACWY conjugate vaccines most widely used in U.S. clinical practice today. Both were evaluated for immunogenicity during licensure, and CDC does not recommend one brand over the other for the age ranges where both are approved. The choice mostly comes down to what a clinic stocks and which product fits the patient’s age.
Understanding this MenACWY versus MenB split also matters for immigration medical exams, since the vaccines required for immigration depend on age-specific ACIP schedules that civil surgeons apply during the Form I-693 review.
How age approvals and dosing schedules actually differ
The clearest way to compare Menactra and Menveo is by age indication, since that single variable often decides which product a clinic reaches for.
Menactra is approved for people from 9 months through 55 years, with no infant-specific series below that age. Menveo is approved starting at 2 months and running through 55 years, which makes it the only option of the two for infants who need meningococcal protection earlier, typically because of a specific medical risk factor or an outbreak setting.
Presentation adds another layer. Menveo comes in both a two-vial formulation, which requires reconstituting a lyophilized component with a liquid conjugate before injection, and a one-vial liquid formulation. According to CDC’s overview of meningococcal vaccines, the one-vial presentation carries its own, higher lower-age limit compared to the two-vial version, so clinics vaccinating infants need to confirm which Menveo presentation is in the refrigerator before drawing it up. Menactra, by contrast, is supplied as a single liquid vial with no reconstitution step.
Here is how the core specifications line up:
- Menactra: approved 9 months through 55 years, single-vial liquid presentation, no infant series.
- Menveo (two-vial): approved from 2 months, requires reconstitution, used for infant series starting at 2 months.
- Menveo (one-vial): approved from an older starting age than the two-vial version, no reconstitution needed.
- Both vaccines: cover serogroups A, C, W, and Y; neither covers serogroup B.
For infants who need meningococcal coverage before 9 months, Menveo is the only licensed choice among these two. Once a child reaches the Menactra age floor, most clinics treat the two brands as functionally equivalent for a routine dose, and the decision often comes down to inventory rather than clinical necessity.
Reconstitution also affects workflow in a busy clinic. A two-vial Menveo dose takes an extra step at the point of care, mixing the liquid MenA conjugate with the lyophilized MenCWY component, which adds a few seconds per patient but is not a barrier to same-day vaccination. Clinics that vaccinate large numbers of infants and children sometimes prefer the one-vial Menveo presentation specifically to speed up that process, since it skips the mixing step entirely.
For immigration medical exams, age is often the deciding factor in a way that has nothing to do with brand preference. A 6-month-old applicant who needs meningococcal vaccination as part of a required series can only receive Menveo, since Menactra is not indicated at that age. A 14-year-old applicant, on the other hand, could receive either brand depending on what the civil surgeon’s office has available that day.
What the safety data show about reactions and rare events
Both vaccines have been studied in large clinical trials, and their side effect profiles look similar enough that neither is considered notably safer or riskier than the other for the ages where both are licensed.
Common reactions reported for Menveo in FDA’s clinical trial data include injection-site pain and redness, with solicited local reactions like injection-site pain occurring in roughly 20% to 30% of vaccinated children in trial populations, depending on age group and dose in the series. These reactions are typically mild and resolve within a few days without treatment.
Menactra’s clinical trial results describe a comparable pattern: injection-site tenderness, redness, and swelling are the most frequently reported reactions, along with systemic symptoms such as headache, fatigue, and muscle aches, most often in adolescents and adults rather than younger children.
Common reactions across both vaccines include:
- Local reactions at the injection site, including pain, redness, and swelling.
- Systemic symptoms such as headache, fatigue, irritability in younger children, and muscle aches.
- Fever, which occurs in a subset of vaccinated infants and children and is usually low-grade.
Serious adverse events are rare in the trial data for both products, and post-license monitoring through systems like the Vaccine Adverse Event Reporting System continues to track them. Neither package insert identifies a serious safety signal that is unique to one brand and absent in the other for the shared age ranges.
When counseling a patient or parent before vaccination, it helps to set expectations plainly: soreness at the injection site and mild fatigue are common and not a reason for concern. Signs that warrant urgent medical attention include difficulty breathing, facial or throat swelling, or a high fever accompanied by unusual lethargy, all of which are signs of a rare allergic or systemic reaction rather than an expected vaccine response. Anyone with a history of a severe allergic reaction to a previous dose or to a vaccine component should discuss that history with the clinician before a repeat dose.
When brands are interchangeable and when they are not
CDC generally treats Menactra and Menveo as interchangeable for people who fall within both vaccines’ approved age ranges, meaning a person who started a series with one brand does not need to restart if the next dose is given with the other, as long as the dosing interval and number of doses follow ACIP recommendations. This no-preference stance simplifies things for clinics that stock only one product or that switch suppliers.
Interchangeability breaks down at the edges of the approved age ranges. A child younger than 9 months cannot receive Menactra under any circumstance, since the vaccine is not licensed for that age group, which makes Menveo the only option regardless of what a previous dose used. Combination products add another wrinkle: when a patient needs both MenACWY and MenB vaccination at the same visit, a licensed MenABCWY combination vaccine may reduce the number of injections, but any follow-up MenB dose in that series generally needs to stay consistent with the same combination product’s brand-specific schedule rather than mixing freely with a separate standalone MenACWY brand.
Key interchangeability points to keep in mind:
- Ages 9 months through 55 years: Menactra and Menveo are generally interchangeable for series completion and boosters.
- Under 9 months: only Menveo is licensed, so brand choice is not optional.
- Combination MenABCWY products: follow-up doses should stay consistent with that product’s own schedule rather than switching to a standalone brand mid-series.
There has also been periodic discussion online about Menactra availability, sometimes framed as a discontinuation. Clinics that experience a temporary Menactra supply gap can generally substitute Menveo for patients within Menveo’s approved age range without restarting a series, following the same interchangeability principle CDC applies to routine brand switching. Anyone concerned about a specific supply question should confirm current status directly with their vaccinating clinic rather than relying on secondhand reports.
Dosing schedules and administration by age group
Dosing details vary meaningfully by age, and getting them right matters both for disease protection and for accurate documentation on immigration paperwork.
- Infants starting at 2 months (Menveo only): a four-dose series is typically given at 2, 4, 6, and 12 months when Menveo is indicated for a younger child, most often due to an underlying risk factor.
- Children and adolescents 9 months and older (either brand): a single primary dose is standard for most healthy people in this range who have not previously been vaccinated, with the routine adolescent dose given at 11 or 12 years.
- Adolescent booster at 16 years: CDC recommends a booster dose around age 16 to maintain protection through the years of highest meningococcal risk, since immunity from the preteen dose wanes over time.
- Adults with ongoing risk factors: people with certain immune conditions, laboratory workers exposed to the bacteria, or those traveling to higher-risk regions may need a single dose or a booster depending on prior vaccination history and current risk.
Administration itself is straightforward for both products: an intramuscular injection, usually in the deltoid for older children and adults or the thigh for infants. The practical difference clinics notice is at the preparation step. Two-vial Menveo requires reconstituting the liquid MenA component with the lyophilized MenCWY powder immediately before injection, while Menactra and one-vial Menveo are ready to draw from a single vial.
For Form I-693 purposes, the civil surgeon’s office documents the specific vaccine given, the date, and the lot information as part of the vaccination record. Applicants who already completed a meningococcal series overseas should bring that documentation to the appointment so the civil surgeon can determine whether it satisfies the requirement without a repeat dose.
What this means for your Form I-693 civil surgeon exam
Civil surgeons follow CDC’s vaccination technical instructions for civil surgeons when deciding which vaccines an applicant needs and how to document them on Form I-693. Age-specific approvals for Menactra and Menveo matter here in a very concrete way: if an applicant is younger than 9 months and needs meningococcal vaccination, Menveo is the only vaccine the civil surgeon can legally administer, regardless of what the clinic normally stocks.
Civil surgeons generally accept reliable foreign vaccination records when they show the right vaccine, date, and dosing interval consistent with ACIP recommendations. When those records are missing, incomplete, or do not meet the required intervals, the civil surgeon will typically administer the vaccine during the visit and document it directly on the form rather than accepting an unverifiable record.
A few points that reduce the chance of a delay:
- Bring original vaccination records, not photocopies or summaries, since civil surgeons need to verify dates and vaccine names directly.
- Have foreign-language records translated before the appointment when possible, since this speeds up review.
- Ask about titer testing if written records are unavailable and there is a question about prior immunity, though titers are more commonly used for other vaccines than for meningococcal disease specifically.
- Expect the civil surgeon to annotate the form as provided, previously documented, or not age-indicated, since a clear annotation is what prevents a Request for Evidence.
Pro Tip: If you are not sure whether your overseas meningococcal vaccination record will be accepted, bring it to your appointment anyway. Civil surgeons can only evaluate what is in front of them, and a document review takes far less time than an unnecessary repeat vaccination.
Applicants who want a deeper walkthrough of how vaccination requirements interact with the rest of the exam can review the complete guide to Form I-693 for a fuller picture of civil surgeon responsibilities.
Getting ready for your appointment
A little preparation before your immigration medical exam can prevent a second visit later. The single biggest factor in avoiding delays is bringing complete, original documentation of any vaccines you already received, including meningococcal vaccination if it applies to your age group or history.
Before your appointment:
- Gather original immunization records, including any documents from vaccinations given outside the United States.
- Arrange translation in advance if your records are not in English, since civil surgeons need to read dates and vaccine names clearly.
- Expect brief consent and counseling before any vaccine is given, covering what reactions are normal and what to watch for afterward.
- Ask about timeframes upfront, since standard processing generally takes about 3 days while an expedited option can complete the exam in about 2 days.
If your records show a gap or an interval that does not meet ACIP criteria, the civil surgeon may need to administer a dose during your visit, which is normal and does not usually require a separate appointment. Titer testing is occasionally used when there is a real question about prior immunity to a specific disease, though for most applicants a documented vaccination history is enough. Guidance on resolving missing vaccine documentation covers this process in more detail if you are unsure what to expect.
The bottom line on choosing between these vaccines
For most people, the choice between Menactra and Menveo is not really a choice at all: it is dictated by age. Anyone younger than 9 months who needs meningococcal vaccination can only receive Menveo, while people 9 months and older can generally receive either brand with no meaningful difference in protection against serogroups A, C, W, and Y.
The practical takeaway for immigration medical exams is documentation, not brand preference. Bring complete, original vaccination records to your Form I-693 appointment, expect the civil surgeon to check age-appropriate requirements against CDC’s technical instructions, and know that a missing or incomplete record usually means a dose given on the spot rather than a denied application.
Does insurance cover the cost of either vaccine
Cost for Menactra or Menveo depends heavily on where the vaccine is given and what insurance, if any, applies. Under the Affordable Care Act, most private insurance plans cover ACIP-recommended vaccines, including routine adolescent MenACWY doses, without a copay when received from an in-network provider. Medicaid programs generally cover recommended vaccines for eligible children and adults as well, though coverage details vary by state program.
For immigration medical exams specifically, vaccination is typically bundled into the overall exam service rather than billed as a separate line item comparable to a routine pediatric visit. Clinics that specialize in Form I-693 exams, including ImmigrationMedicalExams, structure pricing around flat packages for the exam itself, with additional vaccinations priced according to what is needed. Applicants without insurance coverage for the immigration exam should ask directly what a specific clinic’s pricing structure includes before the appointment, since exam pricing and routine vaccine insurance coverage are not the same thing.
Anyone uncertain about their own insurance coverage for a specific vaccine should confirm directly with their insurer or state Medicaid program, since coverage rules are set at the plan or program level rather than by the vaccine manufacturer.
Can these vaccines be given alongside other shots
Both Menactra and Menveo can generally be given at the same visit as other routine vaccines, which is one reason the adolescent platform (ages 11 to 12) often includes MenACWY alongside Tdap and HPV vaccination in a single appointment. CDC’s guidance on meningococcal vaccine recommendations supports coadministration with other age-appropriate vaccines using separate injection sites.
The one scenario that requires more care is when a patient needs both MenACWY and MenB protection at the same visit. A licensed MenABCWY combination product can cover both in fewer injections, but once that combination product is started, follow-up doses in the series should stay consistent with its own schedule rather than switching to standalone MenACWY or MenB brands partway through. Outside of that specific combination scenario, mixing Menactra or Menveo with unrelated vaccines like Tdap, HPV, or annual influenza vaccination at the same visit is standard practice and does not require spacing them apart.
Anyone with questions about a specific combination of vaccines needed at one visit should raise it directly with the vaccinating clinician, since individual medical history can occasionally change the recommended approach.
How long does protection last with each vaccine
Because invasive meningococcal disease is rare in the United States, researchers rely mostly on immunogenicity data (how well a vaccine triggers antibody production) rather than large field-effectiveness studies to judge how well Menactra and Menveo work. The CDC Pink Book chapter on meningococcal disease notes that both vaccines produce strong antibody responses in trials, but that protection wanes over time in both cases, which is the underlying reason ACIP recommends a booster at age 16 rather than treating the preteen dose as lifelong protection.
Neither package insert nor CDC guidance identifies a meaningful difference in how long protection lasts between the two brands. The booster schedule is the same regardless of which brand a person received initially, and switching brands between the original dose and the booster does not appear to change that waning pattern based on current guidance.
Because disease is uncommon, decisions about which vaccine to use come down to age eligibility and presentation logistics rather than any documented difference in how long one brand’s protection outlasts the other’s.
Clinic perspective: what we see with vaccination records
We specialize exclusively in immigration medical exams and Form I-693, which means we spend our days reviewing vaccination histories against ACIP requirements rather than treating general illness. The most common issue we see with meningococcal vaccination is not the wrong brand, it is incomplete documentation: a record that lists a vaccine name without a date, or a series that skipped an interval ACIP requires.
Our flat-package pricing is built to prevent the cost surprises that come from repeat visits, and most exams complete on our standard 3-day timeline, with a 2-day expedited option for applicants facing a filing deadline. We have specialized in immigration medical examinations since 2007, and we regularly work with applicants who ran into vaccination documentation problems at a previous exam elsewhere.
— ImmigrationMedicalExams Medical Team
Schedule your exam and vaccination review
If you need meningococcal vaccination as part of your Form I-693, or you simply want your existing records reviewed by someone who does this every day, our clinic handles the full exam, including vaccination review and administration, on-site lab testing, titer testing when needed, and sealed I-693 delivery, all under one flat-package price.
Most applicants complete the process through our standard 3-day exam, and anyone working against a filing deadline can choose our 2-day expedited option instead. Online scheduling is available 24/7, so you can book a time that works around your own schedule rather than waiting for office hours. Check current pricing and package details or book your appointment directly through our exam services page.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
FAQ
Are Menveo and Menactra interchangeable?
For people between 9 months and 55 years old, CDC generally treats the two brands as interchangeable for completing a series or receiving a booster. Below 9 months, only Menveo is licensed, so interchangeability does not apply.
Which meningococcal vaccine is used in the United States?
Both Menactra and Menveo are used in the United States, along with combination products that pair MenACWY with MenB coverage in a single vaccine. CDC does not prefer one MenACWY brand over the other for ages where both are approved.
Why is Menactra being discontinued?
Reports of Menactra supply changes should be confirmed directly with a vaccinating clinic, since availability can shift by location and time. When a temporary supply gap occurs, clinics can generally substitute Menveo for patients within Menveo’s approved age range without restarting the series.
What vaccine replaced Menactra?
No single vaccine has formally replaced Menactra in U.S. recommendations. Menveo remains available across a wider age range, starting at 2 months compared to Menactra’s 9-month floor, and clinics facing a Menactra shortage typically use Menveo as the substitute for eligible ages.